Physician profile
Daniel Gonzalez Abascal
NPI 1003376179
$1,118.22
in general payments reported to CMS, 2019-2025
11 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $272.51 | 2025 | Versacross Access Solution, Watchman Flx |
| Abbott Laboratories | $255.67 | 2025 | Mitraclip, Triclip |
| Shockwave Medical, INC | $200.81 | 2025 | |
| Scpharmaceuticals INC. | $145.84 | 2025 | |
| Alnylam Pharmaceuticals INC. | $64.90 | 2025 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $49.54 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.07 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.99 | 2025 | Lifevest |
| Pfizer INC. | $23.95 | 2025 | |
| Cleerly, INC. | $17.83 | 2025 | Cleerly Labs, Cleerly Ischemia |
| E.R. Squibb & Sons, L.L.C. | $16.11 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gonzalez Abascal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.